Valeant to distribute Intendis' products in UK
Germany's Intendis GmbH has signed a distribution agreement for the sale of a range of its products in the UK, with local firm Valeant Pharmaceuticals. This includes Finacea, a new topical product for the treatment of rosacea, which will be launched to medical professionals this week.
The deal is part of Intendis' strategy to expand its presence in markets where the company does not have its own subsidiaries. "This agreement with Valeant offers us good opportunities for growth in one of the world's largest dermatology markets," said Wolfgang Kehr, chief executive of Berlin-headquartered Intendis, adding that Valeant will serve the market with a dedicated specialist dermatology sales and marketing organization.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze